Skip to Main Content

Latest News

March 28, 2006
Also appeared in print April 3, 2006, p. 12


RNAi Works In Monkeys

Liposome system delivers short RNAs, gene silencing, and sustained cholesterol reduction

Celia Henry Arnaud

The gene-silencing technique RNA interference has moved a step closer to becoming a viable therapeutic approach. Scientists at Alnylam Pharmaceuticals in Cambridge, Mass., used RNAi in monkeys to silence the gene for apolipoprotein B (ApoB), a protein involved in cholesterol metabolism. The study was published in the online edition of Nature on Sunday (Nature, published online March 26, Muthiah Manoharan, vice president for drug discovery at Alnylam, also described the work on Monday in a symposium sponsored by the Division of Medicinal Chemistry at the ACS national meeting in Atlanta.


Silence, Please A liposomal system developed by Protiva Biotherapeutics was used for long-acting systemic delivery of siRNAs in monkeys.

Tracy S. Zimmermann and coworkers gave monkeys a single injection of a short interfering RNA (siRNA) in a liposomal formulation optimized for delivery to the liver. Within 48 hours, expression of the ApoB gene in the liver dropped by more than 90%. The levels of ApoB, serum cholesterol, and low-density lipoproteins (commonly known as "bad" cholesterol) also dropped significantly. The effects lasted for 11 days.

In an earlier study with mice, the siRNA was conjugated to cholesterol (C&EN, Nov. 15, 2004, page 9). The liposomal delivery system was effective with doses as low as 1 mg/kg of body weight. "We're continuing to optimize the use of chemical conjugates," says John Maraganore, president and CEO of Alnylam. "At the same time, we've been exploring other ways of delivering siRNAs systemically. We believe that multiple technologies can be brought to bear."

John J. Rossi, a molecular biologist who studies RNAi at the Beckman Research Institute of the City of Hope in Duarte, Calif., cites as an important advance the fact that a lower dose is needed with the current delivery system than with the cholesterol conjugate. "The amount of material that's going to be needed to get a systemic effect is much less than shown previously with the cholesterol-tagged molecule," he says.

Although Alnylam has yet to declare its first candidate for systemic RNAi, the company continues to move toward clinical trials. "With liposomal technologies, we have a near-term opportunity and solution that can be used to begin to build our clinical pipeline," Maraganore says. "We're now in the position where we can begin to advance systemic RNAi therapeutics toward human clinical testing as early as the next 18 to 24 months.???

Chemical & Engineering News
ISSN 0009-2347
Copyright © 2010 American Chemical Society


Daily dispatches by C&EN reporters from the 2006 ACS Spring National Meeting in Atlanta.

Related Story

Articles By Topic